Human Granzyme B DuoSet ELISA, 5 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human Granzyme B DuoSet ELISA, 5 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: GZMB

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human Granzyme B DuoSet ELISA, 5 Plate

• C11
• CCPI
• CGL1
• CGL-1
• CSPB
• CSP-B
• CTLA1
• CTLA-1
• CTSGL1
• Fragmentin-2
• Granzyme B
• Granzyme-2
• GranzymeB
• GRB
• GrzB
• GZMB
• HLP
• SECT

Background

Granzyme B is a member of the granzyme family of serine proteases found specifically in granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells (1, 2). Granzyme B plays an essential role in granule-mediated apoptosis utilizing the substrates in this pathway, such as Caspase 3, Caspase 8 and Bid (3, 4). Recent research indicates expanded Granzyme B functionality to include extracellular roles along with its classical pro-apoptotic function. It has been found that Granzyme B is an important mediator of skin injury, repair and inflammation (4) through extracellular substrates including Laminin, VE-Cadherin, Fibronectin and the proteoglycans Aggrecan (3) and Decorin (4). 

As one of the five Granzymes (A, B, H, K and M) identified in the human genome, Granzyme B (32kDa) (5) is the most widely researched in terms of its biological function and its utility in health and disease (4). It is synthesized as a precursor (247 residues) with a signal peptide (residues 1-18), a pro-peptide (residues 19-20), and a mature chain (residues 21-247) (6-8). Once inside granules, Granzyme B is fully processed into the mature chain and becomes an active protease when the pro-peptide, Gly-Glu is removed from the N-terminus by cleavage with Cathepsin C (9). The protease activity of Granzyme B is tightly controlled by Serpin B9/ Protease Inhibitor 9 (9). The amino acid sequence of human Granzyme B is 71%, 69%, and 68% identical to its canine, rat, and mouse counterparts, respectively. 

Granzymes have been shown to modulate inflammation, and Granzyme B plasma levels have been found higher with atopic dermatitis and psoriasis when compared to healthy controls. This is in contrast to Granzyme A plasma levels which remain unchanged (10). Serum from patients with Crohn's disease have significantly higher Granzyme B levels than controls (11). 

Publications for Granzyme B (DY2906-05)(22)

Publications using DY2906-05

• Bang, HJ;Lee, KH;Park, MS;Sun, EG;Cho, SH;Chung, IJ;Shim, HJ;Bae, WK; Dynamic changes in immune cells in humanized liver metastasis and subcutaneous xenograft mouse models Scientific reports 2024-09-02 [PMID: 39223155] (Xenograft)
• Park, E;Mun, HJ;Seo, E;Hwang, S;Lee, JH;Song, S;Sung, H;Kim, HY;Kwon, MJ; CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo Biomedicines 2024-01-22 [PMID: 38275419] (Human)
• Wu, WC;Shiu, C;Tong, TK;Leung, SO;Hui, CW; Suppression of NK Cell Activation by JAK3 Inhibition: Implication in the Treatment of Autoimmune Diseases Journal of immunology research 2023-12-08 [PMID: 38106519] (Human)
• Sugi, T;Katoh, Y;Ikeda, T;Seta, D;Iwata, T;Nishio, H;Sugawara, M;Kato, D;Katoh, K;Kawana, K;Yaguchi, T;Kawakami, Y;Hirai, S; SCD1 inhibition enhances the effector functions of CD8+ T cells via ACAT1-dependent reduction of esterified cholesterol Cancer science 2023-10-25 [PMID: 37879607] (Human)
• Mondal, T;Gaur, H;Wamba, BEN;Michalak, AG;Stout, C;Watson, MR;Aleixo, SL;Singh, A;Condello, S;Faller, R;Leiserowitz, GS;Bhatnagar, S;Tushir-Singh, J; Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer Cell death and differentiation 2023-10-14 [PMID: 37838774] (Human)
• Kobayashi, E;Kamihara, Y;Arai, M;Wada, A;Kikuchi, S;Hatano, R;Iwao, N;Susukida, T;Ozawa, T;Adachi, Y;Kishi, H;Dang, NH;Yamada, T;Hayakawa, Y;Morimoto, C;Sato, T; Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies Cells 2023-08-14 [PMID: 37626869] (Human)
• Berlin, F;Mogren, S;Ly, C;Ramu, S;Hvidtfeldt, M;Uller, L;Porsbjerg, C;Andersson, CK; Mast Cell Tryptase Promotes Airway Remodeling by Inducing Anti-Apoptotic and Cell Growth Properties in Human Alveolar and Bronchial Epithelial Cells Cells 2023-05-22 [PMID: 37408273] (Human)
• YS Lim, AG Lee, X Jiang, JM Scott, A Cofie, S Kumar, D Kennedy, DJ Granville, H Shin NK cell-derived extracellular granzyme B drives epithelial ulceration during HSV-2 genital infection Cell Reports, 2023-04-17;42(4):112410. 2023-04-17 [PMID: 37071533] (Human)
• D Rasoulouni, N Santana-Ma, A Gutwillig, L Farhat-You, L Tal, S Amar, M Milyavsky, SSNA Muddineni, N Solomon, H Shpilt, S Dotan, N Pilpel, C Waskow, M Feinmesser, P Rider, Y Carmi T Cells Expressing a Modified FcgammaRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors Cancer Immunology Research, 2023-06-02;0(0):OF1-OF18. 2023-06-02 [PMID: 37070661] (Human)
• Y Wang, Y Zhao, W Guo, GS Yadav, C Bhaskarla, Z Wang, X Wang, S Li, Y Wang, Y Chen, D Pattarayan, W Xie, S Li, B Lu, US Kammula, M Zhang, D Yang Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response Science Advances, 2022-12-07;8(49):eadd0005. 2022-12-07 [PMID: 36475797] (Human)
• J Heath, W Chour, J Choi, J Xie, M Chaffee, T Schmitt, K Finton, D Delucia, A Xu, Y Su, D Chen, R Zhang, D Yuan, S Hong, A Ng, J Butler, R Edmark, L Jones, K Murray, S Peng, G Li, R Strong, J Lee, J Goldman, P Greenberg Large libraries of single-chain trimer peptide-MHCs enable rapid antigen-specific CD8+ T cell discovery and analysis Research square, 2022-11-18;0(0):. 2022-11-18 [PMID: 36415462] (Human)
• SB An, BG Yang, G Jang, DY Kim, J Kim, SM Oh, N Oh, S Lee, JY Moon, JA Kim, JH Kim, YJ Song, HW Hyun, J Kim, K Lee, D Lee, MJ Kwak, BK Kim, YK Park, CP Hong, JH Kim, HS Lim, MS Ryu, HT Jin, SW Lee, YS Chang, HS Park, YC Sung, MH Jang Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy Nature Communications, 2022-09-27;13(1):5669. 2022-09-27 [PMID: 36167830] (Human)
• C Vetrei, M Passariell, G Froechlich, R Rapuano Le, E Sasso, N Zambrano, C De Lorenzo Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC Cancers, 2021-12-27;14(1):. 2021-12-27 [PMID: 35008285] (Human)
• K Alishah, M Birtel, E Masoumi, L Jafarzadeh, HR Mirzaee, J Hadjati, RH Voss, M Diken, S Asad CRISPR/Cas9-mediated TGFbetaRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro Journal of Translational Medicine, 2021-11-27;19(1):482. 2021-11-27 [PMID: 34838059] (Human)
• R Serrano, C Coch, C Peters, G Hartmann, D Wesch, D Kabelitz Monocyte-dependent co-stimulation of cytokine induction in human gammadelta T cells by TLR8 RNA ligands Scientific Reports, 2021-07-27;11(1):15231. 2021-07-27 [PMID: 34315922] (Human)
• E Marcq, JRM Van Audena, J De Waele, C Merlin, P Pauwels, JP van Meerbe, SA Fisher, ELJ Smits The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3 Cancers, 2021-01-14;13(2):. 2021-01-14 [PMID: 33466653] (Human)
• H Jonescheit, HH Oberg, D Gonnermann, M Hermes, V Sulaj, C Peters, D Kabelitz, D Wesch Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on gammadelta T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells Cells, 2020-05-06;9(5):. 2020-05-06 [PMID: 32384638] (Human)
• DP Muñoz, SM Yannone, A Daemen, Y Sun, F Vakar-Lope, M Kawahara, AM Freund, F Rodier, JD Wu, PY Desprez, DH Raulet, PS Nelson, LJ van 't Vee, J Campisi, JP Coppé Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging JCI Insight, 2019-06-11;5(0):. 2019-06-11 [PMID: 31184599] (Human)
• K Otterdal, A Berg, AE Michelsen, S Patel, MG Tellevik, CG Haanshuus, B Fevang, P Aukrust, N Langeland, T Ueland Soluble markers of neutrophil, T-cell and monocyte activation are associated with disease severity and parasitemia in falciparum malaria BMC Infect. Dis., 2018-12-18;18(1):670. 2018-12-18 [PMID: 30563486] (Human)
• M Kim, S Pyo, CH Kang, CO Lee, HK Lee, SU Choi, CH Park Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer PLoS ONE, 2018-06-06;13(6):e0198347. 2018-06-06 [PMID: 29874279] (Human)
• JM Yingling, WT McMillen, L Yan, H Huang, JS Sawyer, J Graff, DK Clawson, KS Britt, BD Anderson, DW Beight, D Desaiah, MM Lahn, KA Benhadji, MJ Lallena, RB Holmgaard, X Xu, F Zhang, JR Manro, PW Iversen, CV Iyer, RA Brekken, MD Kalos, KE Driscoll Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-? receptor type I inhibitor Oncotarget, 2017-12-31;9(6):6659-6677. 2017-12-31 [PMID: 29467918] (Human)
• JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway Onco Targets Ther, 2016-07-20;9(0):4425-33. 2016-07-20 [PMID: 27499636] (Human)

FAQs for Granzyme B (DY2906-05). (Showing 1 - 1 of 1 FAQs).

1. wondering what the difference is between your quantikine and duo set elisas?
   • Usually the duosets do not have the entire kit such as plates and buffers, whereas the other kits are complete.

Bioinformatics

• Gene Symbol: GZMB